flosz schreef:
Sanofi-Aventis to Invest in Korea
Multinational pharma giant Sanofi-Aventis will invest W50 billion in Korea's pharmaceutical research and development field over the next five years (US$1=W1,258).
The world's fourth-largest pharmaceutical company has signed a memorandum of understanding with Seoul's Health Ministry to invest in the country's biotechnology industry by supporting clinical tests that seek to develop new drugs.
Company publicity said the decision was based on Korea's outstanding human resources as well as its excellent performance in R&D.
english.chosun.com/site/data/html_dir...**************
Delphi Genetics grants licence to Sanofi Pasteur for antibiotic-free manufacturing of vaccines
15 Jun 2009
- Novel microbiological technique permits biosynthesis of proteins at higher yields and without reliance on antibiotics -
Charleroi, Belgium, June, 15, 2009 - Delphi Genetics SA (“Delphi”) today announced that the company has entered into an agreement with Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, for the manufacture of biological pharmaceuticals using Delphi’s patented StabyExpressTM technology.
StabyExpress is a new approach to stabilising the genetic machinery required to manufacture proteins, the raw materials at the heart of many modern biopharmaceuticals including vaccines, monoclonal antibodies and therapeutic proteins. Biopharmaceuticals represent a growing proportion of marketed drugs worldwide with 15 % of the worldwide pharmaceutical market.
Delphi’s StabyExpress technology improves the efficiency of protein manufacture and at a higher quality than alternative approaches.
Moreover, the technology avoids use of antibiotic resistance genes and is therefore in line with recent FDA and EMEA recommendations against the use of antibiotics in manufacturing of proteins for human and veterinary use. Many biological products currently in clinical development and licensed for sale rely on antibiotic resistance genes in the manufacturing process. The use of the StabyExpress avoids any concern regarding the use of antibiotic resistance and offers next generation biological products a more regulatory-consistent manufacturing strategy.
StabyExpress is a proprietary technology developed by Delphi Genetics. Under the agreement Sanofi Pasteur will have the non-exclusive right to use the technology for a range of vaccines it is planning to manufacture. In exchange for the licence, Delphi will receive milestone payments and royalties. No further financial details of the agreement were disclosed.
www.delphigenetics.com/news-78.html